Patient-Reported Outcomes for Glabellar Line Improvement and Satisfaction With the RelabotulinumtoxinA Ready-to-Use Liquid Formulation: Data From the Phase 3 READY-1 Trial

Summary: This study evaluated the patient-reported outcomes of a liquid form of Botox called RelabotulinumtoxinA (relaBoNT-A) specifically in the treatment of glabellar lines. In a 6-month clinical trial, patients who received the treatment reported noticeably smoother frown lines, with effects starting as early as one week and lasting up to six months. Compared to those who received a placebo, patients treated with relaBoNT-A were much more satisfied with their appearance, felt the results looked natural, and experienced boosts in confidence and emotional well-being.